Jason Fangusaro
Emory University
H-index: 40
North America-United States
Top articles of Jason Fangusaro
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
Neuro-oncology
2024/2/1
Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report
Current Oncology
2024/1/20
XX (XX), 1–1, 2024| https://doi. org/10.1093/neuonc/noae030| Advance Access date 23 February 2024
2024
Pediatric low-grade glioma: State-of-the-art and ongoing challenges
2024/1/1
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the …
2024/3/1
Sabine Mueller
H-Index: 16
Jason Fangusaro
H-Index: 28
David Jones
H-Index: 43
Arie Perry
H-Index: 72
Darren Hargrave
H-Index: 38
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium
2024/2/29
Jason Fangusaro
H-Index: 28
Harpreet Singh
H-Index: 2
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)
Neuro-oncology
2023/12/1
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation
2023/11/1
Jason Fangusaro
H-Index: 28
Yuan Zhu
H-Index: 3
Children's Oncology Group's 2023 blueprint for research: central nervous system tumors
Pediatric Blood & Cancer
2023/9
HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS
Neuro-Oncology
2023/6/1
LGG-23. OUTCOMES UTILIZING BRAF INHIBITION MONOTHERAPY IN BRAFV600E MUTATED PEDIATRIC LOW GRADE GLIOMAS
Neuro-Oncology
2023/6/1
TRLS-11. A PHASE 1 STUDY OF SAVOLITINIB IN RECURRENT, PROGRESSIVE, OR REFRACTORY MEDULLOBLASTOMA, HIGH-GRADE GLIOMA, DIFFUSE INTRINSIC PONTINE GLIOMA, AND CENTRAL NERVOUS …
Neuro-Oncology
2023/6
Jie Huang
H-Index: 9
Jason Fangusaro
H-Index: 28
A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors.
2023/6/1
Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B
Cancers
2023/3/31
Jason Fangusaro
H-Index: 28
The children's brain tumor network (CBTN)-Accelerating research in pediatric central nervous system tumors through collaboration and open science
Neoplasia
2023/1/1
Jo Lynne Rokita
H-Index: 13
David Higgins
H-Index: 9
Yuankun Zhu
H-Index: 8
Bo Zhang
H-Index: 8
Allison M Morgan
H-Index: 2
Nathan Young
H-Index: 24
Meen Chul Kim
H-Index: 7
Christopher Friedman
H-Index: 1
Namrata Choudhari
H-Index: 5
David Haussler
H-Index: 115
Sabine Mueller
H-Index: 16
Michelle Monje-Deisseroth
H-Index: 42
Rintaro Hashizume
H-Index: 28
Amy Smith
H-Index: 2
Matthew Miller
H-Index: 2
Nicolas Gerber
H-Index: 17
Eric Raabe
H-Index: 24
Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials
Neuro-oncology
2022/11/1
Jason Fangusaro
H-Index: 28
Nervous system (NS) tumors in cancer predisposition syndromes
2022/10/1
Jason Fangusaro
H-Index: 28
ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium
American Journal of Neuroradiology
2022/3/1
Clinical activity of mitogen-activated protein kinase–targeted therapies in patients with non–V600 BRAF-mutant tumors
JCO Precision Oncology
2022/8
Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors
medRxiv
2022/2/21
Co-Authors
